October 2, 2024
Ex CEO of Vifor Pharma joins Moderna’s Board of Directors
Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna’s Board of Directors, effective October 2, 2024.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
September 30, 2024
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM
Formycon AG and its commercialization partner Fresenius Kabi jointly said Monday that the U.S. Food and Drug Administration (FDA) has approved FYB202/OtulfiTM1 (ustekinumab-aauz), a biosimilar to Stelara, for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis, the third Formycon biosimilar successfully approved by the FDA.
September 27, 2024
Affluant Medical reports net loss of €9.4 million in H1 202 as it develops three devices
Affluent Medical, a French clinical-stage medical technology company specializing in the international development and industrialization of implantable innovative medical devices, reported a net loss of €9.4 million in H1 2024, compared to a net loss of €8.0 million in the prior year period, citing several majors steps developing its three medical devices.
September 26, 2024
Oxford Drug Design gets a share of a £3 million Collaborative Discovery Programme
Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP) announced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate.
September 26, 2024
Laverock Therapeutics advances in its programmable gene silencing platform
Laverock Therapeutics, a UK-based gene-silencing company with a technology for the development of programmable advanced therapies to tackle major diseases,…
September 25, 2024
Bio-Sourcing gets €2.5M in grants and €10M in equity from the EIC Accelerator
Bio-Sourcing, a pioneering Belgian biotherapeutic company, has secured €2.5M in grants and €10M in equity from the European Innovation Council…
September 25, 2024
Vilobelimab demonstrates significant improvement in reduction of draining tunnels
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today said that Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR
September 24, 2024
DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial
French DBV Technologies has completed screening for the VITESSE phase 3 clinical trial In Q3 2024, exceeding its recruitment goal and successfully closed the screening process for the VITESSE Phase 3 study evaluating the Viaskin® Peanut Patch in peanut allergic children ages 4 – 7 years old.
September 18, 2024
Breas and ovarian cancer newly linked to thousands of gene variants
Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known to increase ovarian cancer risk six-fold and risk of aggressive subtypes of breast cancer four-fold. They found over 3,000 harmful genetic changes that could potentially disrupt its function and increase cancer risk. These findings were confirmed by analysing data from large-scale health databases.
July 18, 2024
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Exscientia has made a deal to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of…